JIA Chenhao, WU Meiqi, GUO Ruijie, NI Jun, CUI Ruixue. Comparative Study of 18F-FDG PET/CT Metabolic Alteration Patterns in Cerebral Amyloid Angiopathy and Alzheimer's Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 263-269. DOI: 10.12290/xhyxzz.2021-0693
Citation: JIA Chenhao, WU Meiqi, GUO Ruijie, NI Jun, CUI Ruixue. Comparative Study of 18F-FDG PET/CT Metabolic Alteration Patterns in Cerebral Amyloid Angiopathy and Alzheimer's Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 263-269. DOI: 10.12290/xhyxzz.2021-0693

Comparative Study of 18F-FDG PET/CT Metabolic Alteration Patterns in Cerebral Amyloid Angiopathy and Alzheimer's Disease

Funds: 

National Key Research and Development Project of China 2018YFC1315200

CAMS Innovation Fund for Medical Sciences 2018-I2M-3-001

More Information
  • Corresponding author:

    CUI Ruixue, E-mail: mmdhmm@126.com

  • Received Date: October 15, 2021
  • Accepted Date: November 18, 2021
  • Issue Publish Date: March 29, 2022
  •   Objective  To compare the metabolism pattern of the brain in patients with cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD), and to evaluate the value of brain imaging of 18F-fluorodeoxy glucose (FDG) positron emission tomography/computed tomography (PET/CT) in differentiating CAA and AD.
      Methods  We retrospectively recruited patients with probable CAA (revised Boston diagnostic criteria) and AD of similar age from December 2020 to June 2021 at Peking Union Medical College Hospital. Patients with normal cognition that underwent 18F-FDG PET/CT during the same period were randomly included as controls. We performed visual analysis and quantitative analysis of PET/CT imaging in the three groups.
      Results  Ten patients with probable CAA (CAA group), 10 patients with AD (AD group), and 11 control subjects with normal cognitive function (control group) that met the inclusion and exclusion criteria were enrolled. Visual analysis showed that, compared with the control group, the AD group showed mostly bilateral symmetrical hypometabolism in temporoparietal lobes, with the most significant hypometabolism in the medial temporal lobe and posterior cingulate gyrus; the CAA group exhibited unspecific cortical hypometabolic areas corresponding to hemorrhage. Quantitative analysis of voxel-based brain metabolism images showed that metabolism in the posterior cingulate gyrus, parahippocampal gyrus, parietal lobe, and medial temporal lobe was significantly reduced in the AD group compared with the control group (P < 0.01); metabolism was significantly reduced in the extensive white matter areas, as well as in the caudate nucleus head, corpus callosum, anterior cingulate gyrus, and lateral temporal cortex in the CAA group (P < 0.01). Quantitative analysis based on brain regions showed that the standardized uptake value ratio (SUVr) of 18F-FDG in the occipital/posterior cingulate (O/PC) was significantly lower in the CAA group than in the AD group (0.91±0.05 vs. 1.07±0.08, P < 0.001); the area under the curve for O/PC SUVr identification of probable CAA and AD was 0.98 (95% CI: 0.93-1.00), with an optimal threshold of 0.96, exhibiting sensitivity of 100% and specificity of 90%.
      Conclusions  Probable CAA and AD patients exhibited distinct brain hypometabolism patterns. O/PC SUVr can be a sensitive indicator for differential diagnosis between CAA and AD.
  • [1]
    Boulouis G, Charidimou A, Greenberg SM. Sporadic Cerebral Amyloid Angiopathy: Pathophysiology, Neuroimag-ing Features, and Clinical Implications[J]. Semin Neurol, 2016, 36: 233-243. DOI: 10.1055/s-0036-1581993
    [2]
    Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy[J]. Brain, 2017, 140: 1829-1850. DOI: 10.1093/brain/awx047
    [3]
    Akers C, Acosta LMY, Considine C, et al. Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy[J]. Curr Neurol Neurosci Rep, 2019, 19: 64. DOI: 10.1007/s11910-019-0981-4
    [4]
    Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy[J]. Neurology, 2010, 74: 1346-1350. DOI: 10.1212/WNL.0b013e3181dad605
    [5]
    Greenberg SM, Charidimou A. Diagnosis of Cerebral Amy-loid Angiopathy: Evolution of the Boston Criteria[J]. Stroke, 2018, 49: 491-497. DOI: 10.1161/STROKEAHA.117.016990
    [6]
    Charidimou A, Farid K, Baron JC. Amyloid-PET in sporadic cerebral amyloid angiopathy: A diagnostic accuracy meta-analysis[J]. Neurology, 2017, 89: 1490-1498. DOI: 10.1212/WNL.0000000000004539
    [7]
    Charidimou A, Farid K, Tsai HH, et al. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 410-417. DOI: 10.1136/jnnp-2017-316851
    [8]
    Farid K, Charidimou A, Baron JC. Amyloid positron emis-sion tomography in sporadic cerebral amyloid angiopathy: A systematic critical update[J]. Neuroimage Clin, 2017, 15: 247-263. DOI: 10.1016/j.nicl.2017.05.002
    [9]
    Planton M, Saint-Aubert L, Raposo N, et al. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study[J]. J Alzheimers Dis, 2020, 73: 1607-1614. DOI: 10.3233/JAD-190625
    [10]
    Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impair-ment, Alzheimer's disease, and other dementias[J]. J Nucl Med, 2008, 49: 390-398. DOI: 10.2967/jnumed.107.045385
    [11]
    Smailagic N, Vacante M, Hyde C, et al. 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2015, 1: Cd010632.
    [12]
    Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prod-romal AD[J]. Neuroimage Clin, 2021, 31: 102754. DOI: 10.1016/j.nicl.2021.102754
    [13]
    Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 1497-1508. DOI: 10.1007/s00259-018-4039-7
    [14]
    Bergeret S, Queneau M, Rodallec M, et al. Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study[J]. Stroke, 2021, 52: 1478-1482. DOI: 10.1161/STROKEAHA.120.032905
    [15]
    Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13: 614-629. DOI: 10.1016/S1474-4422(14)70090-0
    [16]
    Bergeret S, Queneau M, Rodallec M, et al. [(18) F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease[J]. Eur J Neurol, 2021, 28: 1511-1519. DOI: 10.1111/ene.14743
    [17]
    Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. Lancet, 2021, 397: 1577-1590. DOI: 10.1016/S0140-6736(20)32205-4
    [18]
    Gatti L, Tinelli F, Scelzo E, et al. Understanding the Pathophysiology of Cerebral Amyloid Angiopathy[J]. Int J Mol Sci, 2020, 21: 3435. DOI: 10.3390/ijms21103435
    [19]
    Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly[J]. Ann Neurol, 2011, 70: 871-880. DOI: 10.1002/ana.22516
    [20]
    Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. Ⅱ. The distribution of amyloid vascular changes[J]. Stroke, 1983, 14: 924-928. DOI: 10.1161/01.STR.14.6.924
    [21]
    Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review[J]. BMC Neurol, 2009, 9: 3. DOI: 10.1186/1471-2377-9-3
    [22]
    Samuraki M, Matsunari I, Yoshita M, et al. Cerebral Amyloid Angiopathy-Related Microbleeds Correlate with Glucose Metabolism and Brain Volume in Alzheimer's Disease[J]. J Alzheimers Dis, 2015, 48: 517-528. DOI: 10.3233/JAD-150274
    [23]
    Farid K, Hong YT, Aigbirhio FI, et al. Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?[J]. PLoS One, 2015, 10: e0139926. DOI: 10.1371/journal.pone.0139926
    [24]
    Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers[J]. Lancet Neurol, 2017, 16: 661-676. DOI: 10.1016/S1474-4422(17)30159-X
    [25]
    Tomonaga M. Cerebral amyloid angiopathy in the elderly[J]. J Am Geriatr Soc, 1981, 29: 151-157. DOI: 10.1111/j.1532-5415.1981.tb01757.x
  • Cited by

    Periodical cited type(2)

    1. 徐晓霞,朱葛敏,赵瑞. 阿尔茨海默病患者血清Ghrelin的表达水平及临床意义. 川北医学院学报. 2024(02): 169-172 .
    2. 沙宇惠,倪俊. 脑淀粉样血管病的分子影像研究进展. 中华神经科杂志. 2023(08): 932-938 .

    Other cited types(0)

Catalog

    Article Metrics

    Article views (1243) PDF downloads (172) Cited by(2)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close